Clinically reviewed by Dr. Sarah Boss, MD
Suvorexant must not be used with narcolepsy. Stop it and contact a clinician immediately after sleep-driving or another complex sleep behavior. Breathing difficulty, collapse or immediate suicidal danger requires emergency help.
Suvorexant is an insomnia medicine known by the brand Belsomra. It works on orexin signaling, a system involved in maintaining wakefulness. Understanding this mechanism helps explain both its role and its limitations. The decision to use it should still consider other medicines, breathing conditions, mental health, next-day responsibilities and what will happen if the prescription does not provide a useful benefit.
What is suvorexant used for?
Suvorexant is used for difficulty falling asleep, staying asleep or both. It is a dual orexin receptor antagonist rather than a benzodiazepine. The approved insomnia indication should not be expanded into a claim that the medicine treats depression, dementia or substance-use disorders themselves. Different conditions may coexist with insomnia, but they need their own assessment and treatment goals. [1]
Before comparing medicines, describe the problem in practical terms. Do you lie awake at the beginning of the night, wake repeatedly, or wake too early? Are you sleepy at a different time from the schedule you need? Is the next day affected by exhaustion, poor concentration or unplanned sleep? Those details are more informative than simply asking for a stronger sleeping tablet.
How blocking orexin affects sleep
Orexin helps keep the brain awake. Suvorexant blocks orexin receptors and can make it easier to transition into and maintain sleep. The medicine is contraindicated with narcolepsy. This is not a minor technical detail: tell the prescriber about a narcolepsy diagnosis, sudden muscle weakness or unexplained episodes of falling asleep before treatment is selected. [1]
The mechanism differs from that of Z-drugs and melatonin-related medicines, so the tablet strengths cannot be compared as though equal numbers mean equal effects. A switch is a clinical decision, not a mathematical substitution. Ask what a proposed change is intended to improve and what additional precautions apply to the new medicine.
Taking the prescribed tablet
Patient information advises taking suvorexant near bedtime, no more than once in a night, with at least seven hours available in bed afterward. Food can delay the effect. Do not repeat a dose because you remain awake or wake again later. Follow the instructions on the actual prescription and ask the pharmacist about an uncertain missed-dose situation. [2]
Plan for the next morning as well as bedtime. A late dose before an early drive, an overnight flight or responsibility for someone who may need assistance can conflict with the intended schedule. Do not use the medicine simply to make travel pass faster. Discuss those practical situations before treatment rather than trying to improvise around them once already sleepy.
Morning alertness and driving
Suvorexant can impair driving, coordination and alertness the next day, even when a person feels fully awake. Effects may persist after stopping in some circumstances. The prescribing information emphasizes exposure, sleep opportunity and other sedatives when evaluating that risk. Feeling subjectively alert is therefore not sufficient evidence that a safety-critical task can be performed normally. [1] [2]
Tell the clinician about falls, near misses, difficulty waking and changes in work performance. A brief record of timing, actual use and morning functioning can help. Avoid assuming that coffee, a shower or a short walk cancels medication-related impairment. The treatment plan needs to fit the tasks you perform, including caregiving, driving and operating equipment.
Common side effects and unusual sleep experiences
Drowsiness, dizziness, headache, unusual dreams, dry mouth and digestive symptoms may occur. Sleep paralysis and temporary leg weakness are more concerning effects that require prompt medical contact. Describe whether an experience occurred while falling asleep, waking or fully awake. This context helps assessment without requiring you to diagnose the cause yourself. [2]
Some people may hesitate to mention a vivid experience because they are worried about what it means. Report it plainly, including what you remember and whether anyone else observed it. A known possible adverse effect should not be used to dismiss persistent confusion, an injury or a dangerous behavioral change. Seek urgent care for serious symptoms rather than waiting for a routine review.
Complex sleep behavior: when to stop
Stop suvorexant and contact a clinician immediately if you discover sleep-driving, sleepwalking or another activity performed while not fully awake. The person may later have little or no memory of eating, calling someone or leaving the house. The label advises immediate discontinuation after a complex sleep behavior. These events can happen with or without additional sedating substances. [1]
This is a specific safety exception, not a general instruction to stop every medicine whenever sleep is difficult. Explain the actual prescription, other substances used and what happened. Do not substitute a different sleeping tablet from an old supply while awaiting advice. If someone has collapsed, cannot be awakened or has difficulty breathing, use emergency services immediately.
Interactions that change exposure or impairment
Suvorexant is metabolized mainly through CYP3A. Strong inhibitors are not recommended in combination, and moderate inhibitors require a different prescribing approach. Other medicines can reduce exposure and effectiveness. Alcohol adds to psychomotor impairment, while other centrally acting sedatives can add to drowsiness. The label does not recommend combining suvorexant with another medicine used to treat insomnia. [1]
The medication list should include recent antibiotics, antifungals, psychiatric medicines, pain treatments, over-the-counter products and supplements. Ask about grapefruit rather than assuming food products cannot interact. A prescription from a different specialist is not automatically known to the clinician treating insomnia. One shared, current list helps prevent a sleep prescription from being assessed in isolation.
Breathing disease, liver function and individual exposure
Sleep apnea and chronic obstructive pulmonary disease need particular consideration. Evidence from selected study groups cannot guarantee respiratory safety for every person. Severe hepatic impairment is a reason the US label does not recommend use. The product information also notes that factors such as sex and body weight can affect exposure, which is another reason not to copy another person’s prescription. [1]
Describe witnessed breathing pauses, new nighttime breathlessness, recent changes in health and a history of falls. Ask whether the sleep problem itself needs investigation before medication is changed. Improving apparent sleep does not mean that breathing interruptions are being treated. If care is transferred, include the relevant diagnoses and the exact current product, not only the general phrase insomnia medication.
Older adults, cognitive symptoms and dementia research
The label includes a short controlled insomnia study in people with mild to moderate Alzheimer’s disease. Sleep measures improved, but drowsiness and falls were among the adverse effects observed. This is evidence about treating insomnia in a studied population, not evidence that suvorexant reverses Alzheimer’s disease or prevents dementia. Those claims should not be inferred from an improvement in nighttime sleep. [1]
When memory or communication is affected, observations from a carer can help assess benefit and harm. Record nighttime wandering, falls, morning alertness and changes in ordinary activities. Agree who administers the medicine and how duplicate doses will be avoided. Ask what constitutes a useful response for the individual rather than treating longer sleep as automatically better in every circumstance.
Mental health applications and safety
Suvorexant may be prescribed for insomnia in someone receiving mental health care, but it is not an antidepressant. The label warns about worsening depression and suicidal thinking. New suicidal thoughts, marked agitation, unusual behavior or substantial deterioration requires prompt clinical assessment. Immediate danger needs emergency help rather than waiting to see whether a better night of sleep resolves the problem. [1]
Ask how sleep treatment connects with psychotherapy, mood treatment and daytime routines. Describe changes in energy, interest, anxiety and functioning separately from sleep duration. When several medicines change together, keep a clear timeline. It is easier to interpret the treatment response when the team knows what actually changed and what remained the same.
Addiction, misuse and the limits of a detox role
Suvorexant is a Schedule IV controlled substance in the United States and has misuse potential. The prescriber should know about past or current substance-use problems, increasing use or taking tablets for a purpose outside the prescription. This is relevant information for planning care, not a reason to hide concerns or assume that every person using a hypnotic has an addiction. [1]
An insomnia prescription does not establish suvorexant as a treatment for alcohol, benzodiazepine or opioid withdrawal. Do not combine remaining sedatives in an attempt to manage a home detox. A coordinated plan may need to address sleep, physical dependence, mental health and continuing addiction treatment. Our detox-before-rehab guide explains why assessment of the setting and order of care matters.
Stopping: distinguish loss of benefit from withdrawal
In the completed trials described in the label, prolonged suvorexant use did not show evidence of physical dependence, and withdrawal symptoms were not reported after discontinuation. That does not erase misuse risk. It also does not mean that the original insomnia cannot return. A clinical review should distinguish those possibilities instead of automatically applying a benzodiazepine taper model. [1]
Agree why treatment is stopping, how sleep will be supported and when the outcome will be reviewed. If other dependence-forming medicines are involved, their stopping plans need separate attention. Explain any previous interruption and what happened afterward. Do not use another person’s experience as proof that your own prescription can be changed in the same way.
Pregnancy, breastfeeding and continuity of care
Pregnancy and breastfeeding require an individualized discussion based on current product information and clinical need. The same applies when illness, a work change or new caregiving responsibilities reduce the opportunity for uninterrupted sleep. Keep the prescriber informed rather than assuming that a previously suitable bedtime routine remains appropriate indefinitely. [1]
Store the medicine securely and do not share it. Ask a pharmacist about disposal of unused tablets and avoid maintaining overlapping supplies with conflicting instructions. During a handover, include the intended benefit, actual use, adverse effects and the next review date. These practical details support safer care when more than one professional is involved.
Longer-term insomnia support
Cognitive behavioral therapy for insomnia, or CBT-I, is usually recommended first for long-term insomnia. It is a structured treatment addressing sleep-related thoughts and behaviors, not simply advice to go to bed earlier. Discuss access and suitability alongside medication, and assess other conditions that may be maintaining the sleep problem. [3]
The medication-review checklist can help you prepare the three most useful questions: what has improved, what has become harder and what needs to happen next. Ask who is responsible for the prescription and what symptoms require contact before the scheduled review.
Frequently asked questions
Is Belsomra an antidepressant?
No. It is a suvorexant insomnia product. Depression and sleep may both require attention, but the goals and evidence should remain distinct.
Does a dementia sleep study prove dementia prevention?
No. A study measuring insomnia outcomes does not establish that the medicine prevents or reverses the underlying cognitive disorder. [1]
Can I take a second tablet after waking?
Do not repeat the dose during the same night. Persistent awakenings should be discussed with the prescriber rather than managed by adding medication. [2]


